
Individualizing CLL Sequencing and Closing Knowledge Gaps
The panelists discussed why treatment sequencing in chronic lymphocytic leukemia (CLL) no longer follows a single algorithm now that Bruton tyrosine kinase (BTK) inhibitors and venetoclax are available alone or together in the frontline setting.
Episodes in this series

The panelists discussed why treatment sequencing in chronic lymphocytic leukemia (CLL) no longer follows a single algorithm now that Bruton tyrosine kinase (BTK) inhibitors and venetoclax are available alone or together in the frontline setting. They outlined multiple possible pathways and explained that patients who relapse after time-limited therapy generally remain sensitive to these drug classes because resistance is not acquired off treatment. Given durable frontline outcomes, they emphasized selecting the best feasible initial regimen, recognizing that future options such as BTK degraders and bispecific antibodies may change later decisions. The panelists shared key takeaways, including selective use of frontline pirtobrutinib and continued expansion of fixed-duration strategies. They also discussed open questions, including therapy after frontline pirtobrutinib, comparative data among BTK inhibitors, fixed-duration vs continuous treatment, double-refractory disease, and emerging sonrotoclax combinations. They closed by advising comprehensive prognostic testing for every patient and repeat molecular testing before each new line of therapy.
Related to this article







